Demant A/S (OTCMKTS:WILYY) Sees Large Volume Increase – Time to Buy?

Shares of Demant A/S Unsponsored ADR (OTCMKTS:WILYY) saw an uptick in trading volume on Tuesday . 653 shares changed hands during mid-day trading, an increase of 26% from the previous session’s volume of 517 shares.The stock last traded at $21.9875 and had previously closed at $22.50.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on WILYY. UBS Group downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. Sanford C. Bernstein downgraded shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Zacks Research raised shares of Demant A/S to a “hold” rating in a research report on Friday, June 26th. Finally, Morgan Stanley upgraded shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Demant A/S Price Performance

The firm has a 50-day moving average price of $20.89 and a two-hundred day moving average price of $17.72. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.36 and a quick ratio of 1.00.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.